See feature articles below:
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Article for CPRX
Will there be a bounce for $CPRX after the drastic crash in the share price? This article details the reasons for the price drop but may offer some reason for a near term bounce.
Catalyst Pharmaceuticals CPRX stock crashed over 50% after the company announced that the FDA has requested additional data in its resubmission of a new drug application for Firdapse, a treatment for Lambert-Eaton myasthenic syndrome.
In February, Catalyst hits a major obstacle when it received a “refusal-to-file” letter from the FDA. The regulatory agency determined that Catalyst had not submitted sufficient information for it to complete a preliminary review of Firdapse.
The FDA has now stated that Catalysts needs to submit not one, but two sets of positive results from a studies of patients with Lambert-Eaton myasthenic syndrome. The company will also needs to conduct several toxicology studies.
The issue with these new studies, aside from the fact that Catalyst’s portfolio of approved drugs remains empty, is that they are often very costly and time consuming.
“We are surprised with the FDA’s request for an additional clinical study for Firdapse, but are encouraged that the agency is open to an efficient, small short-term study design. We are currently in discussions with the FDA, and our clinical experts regarding the protocol and logistics for this confirmatory study,” said Catalyst CEO Patrick J. McEnany.
Just 10 days ago, Catalyst reported its fourth-quarter 2015 earnings, posting a loss of 7 cents on R&D expenses that were up over 60% year-over-year. More time and money researching Firdapse is simply something that Catalyst cannot afford right now.
Source – Zacks
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.
Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.